2023
Top advances of the year: Neuro‐oncology
Barden M, Omuro A. Top advances of the year: Neuro‐oncology. Cancer 2023, 129: 1467-1472. PMID: 36825454, DOI: 10.1002/cncr.34711.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsBrain tumorsRecent phase 3 trialAnti-PD-1 immunotherapyCentral nervous system dysfunctionSingle-agent pembrolizumabHigh-dose chemotherapyPhase 3 trialPrimary CNS lymphomaStem cell transplantationLong-term outcomesLimited therapeutic optionsNervous system dysfunctionOngoing clinical trialsClinical trial landscapeDrug Administration approvalBRAF V600E mutationExcellent disease controlConsolidation therapyCNS lymphomaImproved survivalLeptomeningeal metastasesTherapeutic optionsCell transplantationCraniospinal irradiationPatient population
2011
Pharmacotherapy for Primary CNS Lymphoma
Graber JJ, Omuro A. Pharmacotherapy for Primary CNS Lymphoma. CNS Drugs 2011, 25: 447-457. PMID: 21649446, DOI: 10.2165/11589030-000000000-00000.Peer-Reviewed Original ResearchConceptsPrimary CNS lymphomaCNS lymphomaHigh-dose methotrexate-based chemotherapyMore effective chemotherapy regimensRefractory primary CNS lymphomaEffective chemotherapy regimensOptimal chemotherapy combinationReduced-dose radiotherapySingle-agent methotrexateMethotrexate-based chemotherapyStem cell rescueWhole brain radiotherapyHigh-dose chemotherapyLong-term remissionProgression-free survivalOngoing clinical trialsCombination of drugsChemotherapy regimensChemotherapy combinationsChemotherapy optionsRadiotherapy resultsSerious complicationsClinical trialsCell rescueConsolidation treatment